UNSPSC 51392506: Rimiterol hbr

This classification denotes a beta-adrenergic agonist with the molecular formula C12H17NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I29DRR8S3R, chemically known as erythro-.alpha.-(3,4-dihydroxyphenyl)-2-piperidinemethanol hbr, but more generally known as rimiterol hbr, which bears US NIH Compound Identifier 5458580. European Medicines Agency schedules rimiterol hbr or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10324MIG.

Most nations, for tariff purposes, schedule rimiterol hbr under HS 29333999. SMILES: C1CC(C(CC1[C@H]([C@@H]2CCCCN2)O)O)O.BR.

UNSPSC 51392506 Rimiterol hbr is a Commodity code that presents a significant mismatch between its nominal scope and recent state and local procurement activity. The code nominally identifies a specific pharmaceutical compound (rimiterol hydrochloride, a bronchodilator), yet the two recent opportunities tagged to it involve naloxone procurement and a pharmacy benefit management services inquiry—neither of which involves rimiterol. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, with quarterly deliveries required and all shipping included in bids. The Texas Health and Human Services Commission issued an RFI in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, which addresses wholesale pharmacy contracting and benefit-management strategy rather than a specific drug product. The code shows little relevant recent activity aligned with its intended pharmaceutical compound classification.

Geographic activity is limited to Florida and Texas based on the recent record, with no additional jurisdictions supporting procurement under this code. The issuing bodies are a county health authority (Seminole County) and a state health agency (Texas HHS), neither of which appears to be a repeat buyer under this code in the available window. The mismatch between the code label and the actual solicitations suggests either a taxonomy-assignment error in the state procurement systems or that rimiterol itself sees no active state and local demand currently. Firms evaluating this code should verify the actual product scope with issuing agencies before pursuing opportunities listed under it.